We live product development – transforming ground-breaking ideas into life-saving medication.


26.11.2020 | Press

Press release on VPM's COVID-19 study published in "Neue Presse"

"MHH testet Corona-Impfstoff – besser als Biontech & Co.?" Read more!

09.11.2020 | Press

First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting

Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!

06.11.2020 | Press

Tdap study enters phase III

Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!

31.08.2020 | Press

30 Million Euro Loan from the EIB for TB

VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa. Read more or Stream the ceremony!

23.06.2020 | Press

Hope for the elderly in the corona pandemic

First participants receive VPM1002 in a late-stage phase III clinical trial in Germany. Read more!

26.05.2020 | Press

SARS-CoV-2 study kicks off in Germany

First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic. Read more!

20.03.2020 | Press

Immune boost against the corona virus

In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus. Read more!

02.03.2020 | Press

First volunteer enrolled

Vakzine Projekt Management GmbH: First volunteer enrolled in Phase II/III Study of SIIPL Tdap vaccine in Comparison with Boostrix® in Healthy Participants. More!

20.02.2020 | Press

Modified TB vaccine as a therapy for bladder cancer

Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!

13.02.2020 | News

priMe AVAREF Meeting

The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24th of January 2020 in Nairobi, Kenya.

powered by webEdition CMS